Table 1. Case demographics and tumor responses.

Case No.	Age	Sex	Breed	Tumor type	Primary tumor lesion	TNM classification	Prior therapy	Time from completion of prior therapy to start of trial (days)	Measurable or non-measurable cases	Non-target lesions/target lesionsa	Concomitant medications	Numbers of injection of ca-4F12-E6	Overall tumor response at first evaluation	Tumor response in non-target lesions at first evaluation	Overall best response at subsequent time point	Progression-free survival (days)	Overall Survival (days)
1	10Y	MC	Miniature Dachshund	UC	Bladder	T0N1M1	Surgery, NSAIDs	0	Non-measurable	Lymph node and lung	NSAIDs	6	-	PDb	-	72	139
4	12Y	F	Welsh Corgi	UC	Bladder	T0N1M0	Surgery, NSAIDs	197		Lymph node	-	6	-	PDb	-	112	245
12	6Y	FS	French Bulldog	Undifferentiated sarcoma	Oral	T0N0M1	Radiation (MV)	56		Lung	-	43	-	PD	CR	70	> 917 (alive)
13	14Y	M	Miniature Dachshund	Undifferentiated sarcoma	Oral	T0N0M1	Radiation (MV)	63		Lung	-	7	-	PDb,c	-	63	95
20	15Y	FS	Italian Greyhound	MGT	Mammary gland	T0N0M1	Surgery, chemotherapy	5		Lung	-	11	-	SD	PDb	145	> 145 (ongoing)
22	9Y	FS	French Bulldog	MGT	Mammary gland	T0N0M1	Radiation (kV)	0		Lung and skin	Radiation (kV)	5	-	-	-	25	57
23	14Y	MC	Chihuahua	LC	Lung	T0N0M1	Surgery	352		Lung	-	31	-	PD	PDb	72	> 513 (alive)
2	14Y	FS	Miniature Dachshund	UC	Bladder	T0N0M1	Surgery, NSAIDs, radiation (kV)	0	Measurable	M (skin)	NSAIDs	5	PDb,c	-	-	63	93
3	9Y	F	Shetland Sheepdog	UC	Bladder	T0N2M0	Surgery, NSAIDs	0		M (lymph node)	NSAIDs	6	PD	PD	-	70	> 70
5	10Y	MC	Miniature Dachshund	UC	Prostatic urethra	T0N1M1	Surgery, NSAIDs	0		M (lung)	NSAIDs	6	PD	PD	-	72	> 72 (alive)
6	9Y	M	Golden Retriever	SCC	Nasal	T2N0M0	Surgery, radiation (kV)	34		P	-	20	PR	-	CR	277	472
7	12Y	FS	Toy Poodle	SCC	Oral	T2aN0M0	-	0		P	-	5	PD	-	-	67	> 97
8	4Y	FS	French Bulldog	SCC	Nasal	T3N0M0	Radiation (MV)	35		P	-	7	PD	-	-	70	101
9	9Y	FS	Maltese	SCC	Nasal	T3N0M0	Radiation (MV)	469		P	-	6	NE	-	-	70	73
10	14Y	M	Shiba	SCC	Skin	T2N1M0	Surgery	122		P	-	5	NE	-	-	46	> 66
11	7Y	MC	Weimaraner	SCC	Oral	T3bN1M0	Surgery	30		P	-	2	NE	-	-	14	31
14	13Y	MC	Labrador Retriever	Undifferentiated sarcoma	Oral	T0N0M1	Radiation (MV)	161		M (lung)	-	5	CR	-	-	> 63	> 63 (alive)
15	13Y	FS	Miniature Dachshund	Undifferentiated sarcoma	Oral	T3bN1M1	Radiation (kV), toceranib	0		P	-	2	NE	-	-	14	15
16	1Y	M	Great dane	Undifferentiated sarcoma	Oral	T3bN1M1	Surgery	41		P	NSAIDs	5	NE	-	-	54	56
17	8Y	MC	Chihuahua	Nasal adenocarcinoma	Nasal	T3N0M0(Stage 4d)	Radiation (MV)	404		P	-	37	SD	-	PD	205	> 597 (ongoing)
18	10Y	MC	Toy Poodle	Nasal adenocarcinoma	Nasal	T2N0M0(Stage 2d)	Radiation (MV), NSAIDs	28		P	-	16	SD	-	SD	> 350	> 350 (alive)
19	6Y	M	Shiba	Nasal adenocarcinoma	Nasal	T3N0M0(Stage 3d)	Radiation (MV)	72		P	NSAIDs	5	PD	-	-	70	> 70
21	12Y	FS	Toy Poodle	MGT	Mammary gland	T0N0M1	Surgery, chemotherapy, toceranib	0		M (lymph node)	-	5	PD	SD	-	70	215
24	14Y	MC	Miniature Dachshund	LC	Lung	T2N0M0	-	0		P	-	15	PDc	PD	PDb,c	55	300
25	10Y	FS	French Bulldog	HBT	Heart	-	Radiation (MV), toceranib	0		P	-	10	SD	-	SD	> 479	> 479 (alive)
26	14Y	MC	Miniature Dachshund	HBT	Heart	-	Toceranib	0		P	Toceranib	6		-	-	77	96
27	11Y	FS	Miniature Dachshund	Adenocarcinoma of unknown origin	Intraperitoneal	T2N0M1	Surgery, toceranib	35		P	Toceranib (day385-)	32	SD	SD	PDb	140	583
28	13Y	MC	Standard Poodle	HCC	Liver	T2N0M0	-	0		P	-	20	SD	-	SD	> 217	506
29	10Y	F	Chihuahua	HCC	Liver	T2N1M0	Surgery	1,019		P	-	1	NE	-	-	10	10
30	8Y	MC	Shetland Sheepdog	Colorectal adenocarcinoma	Colon	T2N0M0	Surgery	100		P	-	6	PD	-	-	70	423
31	6Y	M	Rottweiler	OSA	Maxillofacial	T2N-M0	Radiation (MV), chemotherapy	3		P	-	23	SD	-	PR	> 497	> 497 (ongoing)
32	12Y	FS	Miniature Dachshund	OSA	Spleen	T0N0M1	Surgery	347		M (liver)	-	2	PDe	-	-	21	33
33	14Y	MC	Toy Poodle	STS	Skin	T0N0M1	Surgery, radiation (kV)	10		M (skin)	-	4	NE	-	-	46	63
34	12Y	FS	Toy Poodle	STS	Spleen	T0N0M1	Chemotherapy	93		M (liver)	-	3	PDe	-	-	41	51
35	10Y	FS	Mixed	STS	Skin	T4N0M1	Radiation (MV), chemotherapy	519		P	-	3	PDe	-	-	34	36
36	13Y	FS	Miniature Schnauzer	Skin melanoma	Skin	T0N0M1	Surgery	110		M (lung)	-	11	PDb,c	-	PD	74	> 144 (ongoing)
37	14Y	FS	Mixed	Skin melanoma	Skin	T3N1M0	Surgery	55		P	-	2	PDe	-	-	14	27

TNM, tumor, node, metastasis; MC, castrated male; UC, urothelial carcinoma; NSAID, nonsteroidal anti-inflammatory agent; PD, progressive disease; F, female; FS, spayed female; CR, complete response; M, male; MGT, mammary gland tumor; SD, stable disease; LC, lung carcinoma; SCC, squamous cell carcinoma; PR, partial response; NE, not evaluation; HBT, heart base tumor; HCC, hepatocellular carcinoma; OSA, osteosarcoma; STS, soft tissue sarcoma; -, negative or none.

^aTarget lesions were primary (P) or metastatic (M) sites. In dogs with non-measurable disease, the location of non-target lesions was indicated.

^bNew tumor lesions were found.

^cThis showed mixed tumor response.

^dAdams Modified Staging System.

^eClinical progression was observed before the end of the trial.